David Karras, an associate professor of emergency medicine at the School of Medicine, will lead Temple in a five-year-study to stop Methicillin-Resistant Staph Aureus, a serious infection that is a growing problem in America. Temple will be one of five clinical sites participating in the “STOP MRSA” trial. Of the $7.8 million the National Institutes of Health/Division of Microbiology and Infectious Disease is awarding the study, Temple will receive $1.8 million.